EUCTR2008-003318-81-DE
Active, Not Recruiting
N/A
A phase IV, open, randomized, controlled study to demonstrate the non-inferiority of co-administration of GSK Biologicals’ live attenuated measles-mumps-rubella-varicella vaccine and Baxter’s Neisseria meningitidis C conjugate vaccine versus separate administration of each of the vaccines in healthy children aged 12 through 23 months. - MMRV-060
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Active immunization of healthy children during their second year of life against measles, mumps, rubella, varicella and Neisseria meningitidis C diseases
- Sponsor
- GlaxoSmithKline Biologicals
- Enrollment
- 708
- Status
- Active, Not Recruiting
- Last Updated
- 14 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol (e.g. completion of the diary cards, return for follow\-up visits) should be enrolled in the study.
- •A male or female child between, and including, 12 and 23 months of age (including the day before the 24\-month birthday) at the time of vaccination.
- •Written informed consent obtained from the parents or guardians of the subject after they have been advised of the risks and benefits of the study in a language they clearly understand, and before performance of any study procedure.
- •Free of obvious health problems as established by medical history and clinical examination before entering into the study.
- •Previously completed routine childhood vaccinations to the best of parents’ or legal guardians’ knowledge.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) no
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) no
Exclusion Criteria
- •Use of any investigational or non\-registered product (drug or vaccine) other than the study vaccine(s) within six weeks preceding the first dose of study vaccine, or planned use during the study period.
- •Chronic administration (defined as more than 14 days) of immunosuppressants or other immune\-modifying drugs within six months prior to the first vaccine dose. (For corticosteroids, this will mean prednisone, or equivalent, greater than or equal to 0\.5 mg/kg/day. Inhaled and topical steroids are allowed.)
- •Planned administration/ administration of a vaccine not foreseen by the study protocol within six weeks prior until six weeks after the study vaccine dose with the exception of oral polio vaccine (OPV) which can be given at any time; routine inactivated vaccines, except those containing diphtheria or tetanus toxoid, can be administered up to two weeks before the study vaccine dose.
- •Previous vaccination against measles, mumps, rubella, varicella and/or Neisseria meningitidis serogroup C.
- •History of measles, mumps, rubella, varicella and/or Neisseria meningitidis serogroup C diseases.
- •Known exposure to measles, mumps, rubella and/or varicella within 30 days prior to the study start.
- •Any confirmed or suspect immunosuppressive or immunodeficient condition (congenital or secondary), including human immunodeficiency virus (HIV) infection, based on medical history and physical examination (no laboratory testing is required).
- •A family history of congenital or hereditary immunodeficiency.
- •History of allergic disease or reactions likely to be exacerbated by any component of the vaccine(s), including systemic hypersensitivity to neomycin.
- •Major congenital defects or serious chronic illness.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 4
A clinical trial to study safety and immunogenicity of two Hepatitis A vaccines in healthy young children aged between, and including, 18 months to 47 months, using a 0/6 month immunization scheduleCTRI/2010/091/000246Crucell Switzerland AGRehhagstr. 79CH-3018 BerneSwitzerland250
Active, Not Recruiting
Phase 1
Randomized study of three treatment arms; Colon mechanical preparation with oral and intravenous antibiotics versus oral and intravenous or only intravenous antibiotics. To confirm the decrease of infections in the surgical site with the first of the treatment arm after colon surgery.Patients undergoing right hemicolectomyMedDRA version: 21.1 Level: LLT Classification code 10039153 Term: Right hemicolectomy System Organ Class: 100000004865Therapeutic area: Diseases [C] - Digestive System Diseases [C06]EUCTR2019-002002-43-ESFundación Instituto de Investigación Sanitaria Aragón108
Not Yet Recruiting
N/A
A study for comparative evaluation of the effect of drug administration on carotid thickness in patients with thickened carotid type 2 diabetesKCT0006237The Catholic University of Korea, Bucheon St. Mary's Hospital128
Completed
N/A
ong-term follow-up of children who participated at 9-12 months of age in clinical trial PsA-TT-007 in MaliMeningococcal serogroup AInfections and InfestationsISRCTN37623829PATH825
Active, Not Recruiting
Phase 1
Clinical trial to evaluate the effects of Fydrane® and standard protocol on ocular surface after cataract surgery.CataractsMedDRA version: 20.0 Level: PT Classification code 10007739 Term: Cataract System Organ Class: 10015919 - Eye disordersMedDRA version: 20.0 Level: PT Classification code 10063797 Term: Cataract operation System Organ Class: 10042613 - Surgical and medical proceduresTherapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]EUCTR2017-003277-34-ESaboratoires Théa50